Prescribing information

This page/content is for Great Britain healthcare professionals only.

Pluvicto® is indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor (AR) pathway inhibition and taxane-based chemotherapy or who are not medically suitable for taxanes.1


Contact us

To contact a member of the Advanced Accelerator Applications (a Novartis Company) team, please click below to fill in the request form.




Icon of an arrow on the bulls-eye of a target. Show more.

Pluvicto mechanism of action

Pluvicto targets PSMA-positive cells, including prostate cancer cells.1

Show more about Pluvicto mechanism of action


Icon of a magnifying glass. Show more.

Safety profile and efficacy

The efficacy and safety profile of Pluvicto + BSoC were assessed in the VISION trial.2

Show more on the safety profile and efficacy


Icon representing administration of Pluvicto. Read more.

Dosing and administration

Pluvicto is a ready-to-use solution administered intravenously.1

Read more about dosing and administration


AR, androgen receptor; BSoC, best standard of care; mCRPC, metastatic castration-resistant prostate cancer; PSMA, prostate-specific membrane antigen.


  1. Pluvicto® Great Britain Summary of Product Characteristics.
  2. Sartor O, et al. N Engl J Med 2021;385(12):1091–1103.
AAA-PSMA-UK-0613 | January 2024

Ask Speakers


Medical Information Request